This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sargent, L. M. Articles by Pitot, H. C. Search for Related Content PubMed PubMed Citation Articles by Sargent, L. M. Articles by Pitot, H. C.

Tamoxifen Induces Hepatic Aneuploidy and Mitotic Spindle Disruption after a Single in Vivo Administration to Female Sprague-Dawley Rats¹

McArdle Laboratory for Cancer Research, The Medical School, University of Wisconsin, Madison, Wisconsin 53706 [L. M. S., Y. P. D., N. B., C. A. S., P. S., G. L. S., H. C. P.]; Medical Genetics, East Carolina University Medical School, Greenville, North Carolina 27858 [J. E. W.]; and Lurie Cancer Center, Northwestern University, Chicago, Illinois 60611 [V. C. J.]

Tamoxifen has found extensive use in the treatment of all stages of human breast cancer. The efficacy of tamoxifen treatment for the prevention of second primary tumors and its chemosuppressive action in animal models have led to initiation of clinical trials to test its efficacy for prevention of this disease in women. Recently, tamoxifen has been shown to induce hepatocellular carcinomas in rats. For determination of the mechanism of induction of these tumors and assessment of the possibility of risk of human cancer development from tamoxifen treatment, female Sprague-Dawley rats (five rats per treatment) were administered tamoxifen at doses ranging from 0.3 to 35 mg/kg. One day after treatment, the rats were sacrificed, and the hepatocytes were isolated and cultured for 50 h. Colcemid was added 3 h prior to harvest, and the hepatocytes were then prepared for karyotypic evaluation. One hundred metaphase spreads were examined per animal. Tamoxifen treatment resulted in the induction of aneuploidy in approximately 70% of the examined hepatocytes at the doses used. In addition, premature condensation (2–10%) and endoreduplication (5–10%) were observed in hepatocytes of rats treated with tamoxifen. Furthermore, exchanges between chromosomes as well as chromosome breakage were observed. Examination of the cultured hepatocytes from rats treated with tamoxifen by electron microscopy demonstrated both unipolar spindles and incompletely elongated spindles. Exposure of rats to a single in vivo dose of tamoxifen produced multiple changes in rat hepatocytes including clastogenic damage at doses comparable to that administered to humans. The occurrence of aneuploidy induction, premature condensation, chromosome breakage, and improper mitotic spindle formation indicates that risk versus benefit of tamoxifen treatment should be carefully evaluated.

¹ This work was supported in part by National Cancer Institute Grants CA-07175, CA-22484, and CA-57245, and by Special Institutional Grant SIG-15 from the American Cancer Society.

² To whom requests for reprints should be addressed, at McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Avenue, Madison, Wisconsin 53706.

Received 3/ 9/94. Accepted 5/19/94.

This article has been cited by other articles:

				K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]

				F. Cortes and N. Pastor Induction of endoreduplication by topoisomerase II catalytic inhibitors Mutagenesis, March 1, 2003; 18(2): 105 - 112. [Abstract] [Full Text] [PDF]

				M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]

				D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]

				W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]

				R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling Cancer Res., October 1, 1999; 59(19): 4829 - 4833. [Abstract] [Full Text] [PDF]

				F. Sauvez, D. S. Drouin, M. Attia, H. Bertheux, and R. Forster Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats Carcinogenesis, May 1, 1999; 20(5): 843 - 850. [Abstract] [Full Text] [PDF]

				P. L. Carmichael, S. Sardar, N. Crooks, P. Neven, I. Van Hoof, A. Ugwumadu, T. Bourne, E. Tomas, P. Hellberg, A. J. Hewer, et al. Lack of evidence from HPLC 32P-post-labelling for tamoxifen–DNA adducts in the human endometrium Carcinogenesis, February 1, 1999; 20(2): 339 - 342. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]